Rosetta initiates in vivo studies of liver cancer
The project, combining Isis’ know-how and IP in antisense chemistry and Rosetta Genomics’ knowhow and proprietary microRNA platform technologies, is the companies’ attempt at harnessing microRNAs’ role as
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.